Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.029
Sell
RSI(14)
33.944
Neutral
STOCH(KDJ)(9,3,3)
24.357
Neutral
ATR(14)
0.126
High Vlolatility
CCI(14)
-159.529
Sell
Williams %R
83.333
Oversold
TRIX(12,20)
-0.363
Sell
StochRSI(14)
0.000
Sell
InspireMD Inc
NSPR2.080USD
-0.030-1.42%
Market hours （ET）Quotes delayed by 15 min
67.71MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of InspireMD Inc
Currency: USD Updated: 2025-11-05Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
InspireMD Inc's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
2
analysts
Buy
Current Rating
4.500
Target Price
+111.76%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
InspireMD Inc Highlights
StrengthsRisks
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 35.54% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 7.01M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 7.01M.
Fairly Valued
The company’s latest PE is -2.57, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 17.20M shares, increasing 18.55% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 0.00 shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.67.
Financial Health
Currency: USD Updated: 2025-11-05The company's current financial score is 5.89, which is lower than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 2.52M, representing a year-over-year increase of 39.39%, while its net profit experienced a year-over-year increase of 61.06%.
Score
Financials
8.36
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data
Quality of Earnings
7.24
Operational Efficiency
2.57
Growth Potential
4.16
Shareholder Returns
7.11
InspireMD Inc's Company Valuation
Currency: USD Updated: 2025-11-05The company’s current valuation score is 7.68, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -2.57, which is -85.61% below the recent high of -0.37 and -116.46% above the recent low of -5.57.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 118/210
No Data
Earnings Forecast
Currency: USD Updated: 2025-11-05The company’s current earnings forecast score is 8.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for InspireMD Inc is 4.50, with a high of 5.00 and a low of 4.00.
Score
Support & Resistance
No Data
Analyst Rating
Based on
2
analysts
Buy
Current Rating
4.500
Target Price
+111.76%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
110
Total
7
Median
9
Average
Company name
Ratings
Analysts
InspireMD Inc
NSPR
2
Medtronic PLC
MDT
35
Stryker Corp
SYK
33
Abbott Laboratories
ABT
32
Zimmer Biomet Holdings Inc
ZBH
30
Dexcom Inc
DXCM
30
1
2
3
...
22
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
No Data
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-11-05The company’s current price momentum score is 6.72, which is lower than the Healthcare Equipment & Supplies industry's average of 6.82. Sideways: Currently, the stock price is trading between the resistance level at 2.42 and the support level at 1.93, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
2.185
Sell
MA10
2.220
Sell
MA20
2.288
Sell
MA50
2.366
Sell
MA100
2.394
Sell
MA200
2.536
Sell
Institutional Confidence
Currency: USD Updated: 2025-11-05The company’s current institutional recognition score is 3.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.40. The latest institutional shareholding proportion is 41.23%, representing a quarter-over-quarter decrease of 24.70%. The largest institutional shareholder is Steven Cohen, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.
Score
Institutional Shareholding
No Data
Risk Assessment
Currency: USD Updated: 2025-11-05The company’s current risk assessment score is 3.23, which is lower than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is 0.64. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.64
VaR
+11.99%
240-Day Maximum Drawdown
+42.97%
240-Day Volatility
+86.38%
Return
Best Daily Return
60 days
+4.60%
120 days
+17.72%
5 years
+100.00%
Worst Daily Return
60 days
-7.21%
120 days
-100.00%
5 years
-100.00%
Sharpe Ratio
60 days
-2.50
120 days
-1.57
5 years
-0.14
Risk Assessment
Maximum Drawdown
240 days
+42.97%
3 years
+50.93%
5 years
+95.85%
Return-to-Drawdown Ratio
240 days
-0.42
3 years
+0.73
5 years
-0.17
Skewness
240 days
+2.39
3 years
+2.74
5 years
+2.59
Volatility
Realised Volatility
240 days
+86.38%
5 years
+95.79%
Standardised True Range
240 days
+8.31%
5 years
+12.27%
Downside Risk-Adjusted Return
120 days
-110.15%
240 days
-110.15%
Maximum Daily Upside Volatility
60 days
+32.29%
Maximum Daily Downside Volatility
60 days
+30.20%
Liquidity
Average Turnover Rate
60 days
+0.65%
120 days
+0.41%
5 years
--
Turnover Deviation
20 days
+66.93%
60 days
+210.83%
120 days
+97.87%
Peer Comparison
Healthcare Equipment & Supplies
InspireMD Inc
NSPR
6.19 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Castle Biosciences Inc
CSTL
8.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
COR
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
TCMD
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AXGN
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Artivion Inc
AORT
8.51 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
